{"id":"be252e16-ea7c-5a8e-8c29-d62aa508033d","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-cd38-knockout-nad","predicate":"no_detected_change_in_recorded_comparison","statement":"Apigenin increased NAD+ in wild-type mouse embryonic fibroblasts but produced no further NAD+ increase in CD38-knockout fibroblasts.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"e0c9e4fe-4a27-5fbf-b130-a0008aeda5df","mechanism_event_label":"Apigenin increased NAD+ in wild-type mouse embryonic fibroblasts but produced no further NAD+ increase in CD38-knockout fibroblasts.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"fdc8e7e5-258c-53e1-bcc4-12f5145e4a45","slug":"whole-cell-nad-plus-content","display_name":"Whole-cell NAD+ content","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e0c9e4fe-4a27-5fbf-b130-a0008aeda5df","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-cd38-knockout-nad-event","event_type":"experimental_observation","label":"Apigenin increased NAD+ in wild-type mouse embryonic fibroblasts but produced no further NAD+ increase in CD38-knockout fibroblasts.","description":"### api-cd38-knockout-nad\n\nApigenin increased NAD+ in wild-type mouse embryonic fibroblasts but produced no further NAD+ increase in CD38-knockout fibroblasts.\nFigure 4 supports CD38 dependence of this NAD endpoint under these conditions, not of every apigenin phenotype.\nModel and exposure: Mouse wild-type and Cd38-null MEFs; 25 micromolar, 6 hours.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin in Cd38-null cells","sequence_order":0,"notes":""},{"entity":{"id":"fdc8e7e5-258c-53e1-bcc4-12f5145e4a45","slug":"whole-cell-nad-plus-content","display_name":"Whole-cell NAD+ content","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"no_detected_change","sequence_order":1,"notes":""},{"entity":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"role":"measured metabolite","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_condition","value_text":"Apigenin in Cd38-null cells","comparator":"Vehicle in Cd38-null cells","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"experimental_condition","value_text":"genetically absent","comparator":"Vehicle in Cd38-null cells","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"mouse-cd38","display_name":"Mouse CD38","entity_type_key":"protein"}},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin in Cd38-null cells\", \"comparator\": \"Vehicle in Cd38-null cells\", \"endpoint\": \"Apigenin increased NAD+ in wild-type mouse embryonic fibroblasts but produced no further NAD+ increase in CD38-knockout fibroblasts.\", \"effect_direction\": \"no_detected_change\", \"combination\": \"joint\", \"conditions\": [{\"entity_slug\": \"apigenin\", \"state\": \"Apigenin in Cd38-null cells\"}, {\"entity_slug\": \"mouse-cd38\", \"state\": \"genetically absent\"}]}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Mouse wild-type and Cd38-null MEFs; 25 micromolar, 6 hours.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin increased NAD+ in wild-type mouse embryonic fibroblasts but produced no further NAD+ increase in CD38-knockout fibroblasts.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-cd38-knockout-nad; Figure 4 supports CD38 dependence of this NAD endpoint under these conditions, not of every apigenin phenotype.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"d2125110-0772-5681-a47b-f7a9b59dce73","evidence_kind":"source_excerpt","locator":"Lines 184-190","start_line":184,"end_line":190,"excerpt":"### api-cd38-knockout-nad\n\nApigenin increased NAD+ in wild-type mouse embryonic fibroblasts but produced no further NAD+ increase in CD38-knockout fibroblasts.\nFigure 4 supports CD38 dependence of this NAD endpoint under these conditions, not of every apigenin phenotype.\nModel and exposure: Mouse wild-type and Cd38-null MEFs; 25 micromolar, 6 hours.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Mouse wild-type and Cd38-null MEFs; 25 micromolar, 6 hours.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}